Prime Medicine is a pre-commercial gene editing company whose investment thesis is entirely dependent on the clinical and commercial success of its pipeline, as its financials show no sustainable revenue generation.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.24+6.7% vs -$0.26 | $1M-48.7% vs $2M |
Q2 2026 May 7, 2026 | -$0.28-16.7% vs -$0.24 | $856,000-63.2% vs $2M |
Q2 2026 Mar 3, 2026 | -$0.22+12.0% vs -$0.25 | $842,000-34.6% vs $1M |
Q4 2025 Nov 7, 2025 | -$0.32-14.3% vs -$0.28 | $1M-40.3% vs $2M |
Prime Medicine, Inc. (PRME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MONTREAL--(BUSINESS WIRE)--Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces the launch of a proposed private placement financing of subscription receipts for maximum aggregate gross proceeds of CA$4.0 million (the “Financing”) and that it has received a CA$2.5 million lead order from an institutional investor in connection with the Financing. Each subscription receipt will entitle the holder thereof, upon satisfaction of the Escrow Release Conditions (as defined below),.
PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.
Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of the S&P 500's annual returns with more positive years than all the other quarters. Small cap healthcare/biotech, technology, and consumer cyclicals—like PRME, CRNC, and FOSL—are highlighted as early breakout candidates with strong institutional interest and analyst targets.
Benchmark PRME against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Prime Medicine, Inc. (PRME)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.65 | $839.87M | -4.39 | 55.28% | -4613.11% | -188.27% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — | |
| $2.57 | $394.4M | -4.15 | 25.39% | -157.32% | -196.63% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $14.75 | $146.81M | -2.48 | 181.46% | -8214.47% | -117.05% | — |
Prime Medicine, Inc. (PRME) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Prime Medicine, Inc. (PRME) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 8, 2026·SEC
Jun 8, 2026·SEC
Mar 3, 2026·SEC
Get notified when PRME posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Prime Medicine, Inc. (PRME) stock FAQ — growth, dividends, profitability & financials explained
Prime Medicine, Inc. (PRME) reported $4.1M in revenue over the trailing twelve months. Revenue was $4.6M in fiscal year 2025.
Prime Medicine, Inc. (PRME) revenue fell by 17.9% over the trailing twelve months, compared with the twelve months before.
No. Prime Medicine, Inc. (PRME) reported a net loss of $187.9M over the trailing twelve months.
Prime Medicine, Inc. (PRME) had a return on equity (ROE) of -188.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
Prime Medicine, Inc. (PRME) had negative free cash flow of $156.8M over the trailing twelve months.
